| Popis: |
Megan Catherine Schwarz,1 Silvia Allikmets21Icahn School of Medicine, Mount Sinai Oncological Sciences, New York, NY, USA; 2Faculty of Life Sciences & Medicine, GKT School of Medical Education, King’s College London, London, UKWe thank Lin et al for their interesting study proposing TMED2 overexpression as a potential marker of poor prognosis in breast cancer.1 While the results imply that TMED2 overexpression decreases survival rates, we are hesitant to agree with the authors’ statement claiming its prognostic power until certain aspects of the study are clarified. We further propose recommendations for consideration in future investigations to maximize the potential of this study.View the original paper by Lin and colleagues |
